On March 19, the Central Epidemic Command Center (CECC) announced that according to the recommendations made in the expert meeting of the Advisory Committee on Immunization Practices (ACIP), the clinical benefits of the AstraZeneca vaccine in preventing COVID-19 infection and severe symptoms after infection outweigh the risk of adverse reactions after vaccination, and it is recommended that the AstraZeneca vaccine be offered to the priority groups as planned.